Literature DB >> 16911854

Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients.

Yvonne Vergouwe1, Ewout W Steyerberg, Richard S Foster, Dirk T Sleijfer, Sophie D Fosså, Arthur Gerl, Ronald de Wit, J Trevor Roberts, J Dik F Habbema.   

Abstract

OBJECTIVES: Surgical resection of postchemotherapy retroperitoneal lymph nodes is often performed in patients with advanced nonseminomatous testicular germ cell cancer. We previously developed a model to predict the probability that the lymph nodes contain only necrotic or fibrotic (benign) tissue versus mature teratoma and viable cancer (tumour) to identify patients who actually need resection. The present study used an updated model with new patient data and studied the validity of the updated model across various settings.
METHODS: We combined data of 544 patients from the original model with data of 550 new patients and performed a new logistic regression analysis, which included the same six predictors: histology of the primary tumour, prechemotherapy serum levels of alpha-fetoprotein, human chorionic gonadotropin, lactate dehydrogenase, residual mass size measured on computed tomography, and change in mass size. The validity of the updated model was studied in individual centres. Calibration of the predicted probabilities was assessed graphically and with the Hosmer-Lemeshow test. Discrimination was studied with the concordance (c)-statistic.
RESULTS: The updated model had slightly different, although more precise, regression coefficients. Statistically nonsignificant Hosmer-Lemeshow tests confirmed good calibration in most centres. The c-statistic for all centres except one exceeded 0.80. The updated model was valid over the complete range of predicted probabilities across a broad spectrum of centres.
CONCLUSIONS: This finding gives confidence in the applicability of the model to select patients for resection, particularly patients with small residual masses and low predicted probabilities of benign tissue (i.e., substantial predicted risks of residual tumour).

Entities:  

Mesh:

Year:  2006        PMID: 16911854     DOI: 10.1016/j.eururo.2006.06.047

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  21 in total

1.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

2.  Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes.

Authors:  Yoichi Arai; Yasuhiro Kaiho; Shigeyuki Yamada; Hideo Saito; Koji Mitsuzuka; Shinichi Yamashita; Shunichi Namiki; Haruo Nakagawa; Shigeto Ishidoya; Akihiro Ito
Journal:  Int Urol Nephrol       Date:  2012-05-22       Impact factor: 2.370

3.  Recent developments in the management of germ cell tumors.

Authors:  Pavlos Msaouel; Mehmet A Bilen; Miao Zhang; Matthew Campbell; Jennifer Wang; Shi-Ming Tu
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

4.  Assessing the incremental value of diagnostic and prognostic markers: a review and illustration.

Authors:  Ewout W Steyerberg; Michael J Pencina; Hester F Lingsma; Michael W Kattan; Andrew J Vickers; Ben Van Calster
Journal:  Eur J Clin Invest       Date:  2011-07-05       Impact factor: 4.686

5.  Assessing the discriminative ability of risk models for more than two outcome categories.

Authors:  Ben Van Calster; Yvonne Vergouwe; Caspar W N Looman; Vanya Van Belle; Dirk Timmerman; Ewout W Steyerberg
Journal:  Eur J Epidemiol       Date:  2012-10-07       Impact factor: 8.082

6.  External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer.

Authors:  Cédric Vallier; Pierre-Henri Savoie; Jean-Robert Delpero; Franck Bladou; Gwenaëlle Gravis; Naji Salem; Dominique Rossi; Jochen Walz
Journal:  World J Urol       Date:  2014-01-20       Impact factor: 4.226

7.  Validation of a prediction model for avoiding post-chemotherapy retroperitoneal lymphadenectomy in patients with metastatic nonseminomatous germ cell cancer.

Authors:  Nahid Punjani; Nicholas Power; James J Vanhie; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2016-08       Impact factor: 1.862

8.  Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.

Authors:  Siamak Daneshmand; Hooman Djaladat; Craig Nichols
Journal:  Ther Adv Urol       Date:  2011-08

9.  Clinico-pathological outcomes of post- primary and salvage chemotherapy retroperitoneal lymph node dissection for mixed germ cell tumors, King Hussein Cancer Center experience.

Authors:  Kholoud Alqasem; Ibrahim Abukhiran; Judy Jasser; Tamer Bisharat; Riyad T Ellati; Jakub Khzouz; Ibrahim Al-Saidi; Ali Al-Daghamin
Journal:  Turk J Urol       Date:  2016-12

10.  Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors.

Authors:  Hugh J Lavery; Robert R Bahnson; David S Sharp; Kamal S Pohar
Journal:  Ther Adv Urol       Date:  2009-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.